Posted by Michael Wonder on 13 Jun 2022
Amivas receives authorisation from the MHRA to market artesunate amivas (artesunate) in U.K. for initial treatment of severe malaria
13 June 2022 - Amivas Ireland announced today the MHRA has authorised the Company to commercialise its lead product, Artesunate Amivas (artesunate), in the U.K.
Artesunate Amivas (artesunate) is intended for initial treatment of severe malaria in adults and children.
The approval was based on the recent recommendation by the Committee for Medicinal Products for Human Use (CHMP) to grant such authorisation.
